First-in-human randomized study to assess the safety and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine based on chimpanzee-adenovirus-155 viral vector–expressing RSV fusion, nucleocapsid, and antitermination viral proteins in healthy adults

<p><strong>Background:</strong> Respiratory syncytial virus (RSV) disease is a major cause of infant morbidity and mortality. This Phase I, randomized, observer-blind, placebo- and active-controlled study evaluated an investigational vaccine against RSV (ChAd155-RSV) using the vira...

Full description

Bibliographic Details
Main Authors:	Cicconi, P, Jones, C, Sarkar, E, Silva Reyes, L, Klenerman, P, De Lara, C, Hutchings, C, Moris, P, Janssens, M, Fissette, L, Picciolato, M, Leach, A, Gonzalez Lopez, A, Dieussaert, I, Snape, M
Format:	Journal article
Language:	English
Published:	Oxford University Press 2019

First-in-human randomized study to assess the safety and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine based on chimpanzee-adenovirus-155 viral vector–expressing RSV fusion, nucleocapsid, and antitermination viral proteins in healthy adults

Similar Items